Impact of adherence to antiemetic guidelines on the incidence of chemotherapy-induced nausea and vomiting and quality of life
- 655 Downloads
Background International guidelines are tools enabling physicians to incorporate the latest evidence based clinical information into practice. Objective This study aimed to evaluate the impact of antiemetic guidelines adherence on the incidence of chemotherapy-induced nausea and vomiting (CINV) and patient quality of life. Setting Marmara University Pendik Training and Research Hospital chemotherapy unit, Istanbul, Turkey. Method The study included 100 chemotherapy naive patients. Antiemetic prescribing patterns and their consistency with MASCC/ESMO 2014 guidelines were assessed. Patients recorded incidences of vomiting in a daily dairy and described their nausea using a 7-item Likert Scale. The incidence of CINV was recorded over five days. To assess the patient's quality of life, a modified Turkish version of the Functional Living Index-Emesis (FLIE) questionnaire was administered before and after receiving chemotherapy. A questionnaire on the existence and severity of side effects was developed and administered. Main outcome measures Incidence of side effects on CINV and quality of life according to the FLIE. Results The primary outcome revealed differences in complete control (no emetic episodes, rescue therapy or nausea), FLIE scores and side effects. Guidelines consistency was observed more with acute (A) than with delayed (D) prevention of CINV, with significant differences in complete control between the guideline adherent group (GAG) and the guideline nonadherent group (GNG). Significant differences in the FLIE score were noticed between GAG(D) and GNG(D), and GNG(D) had a higher incidence of diarrhoea, headache, swallowing difficulties and dark-coloured stool. Conclusion Consistency with guidelines resulted in significant reduction in the incidence of both cute and delayed CINV and other side effects, and with improvement of the patient quality of life.
KeywordsAdverse drug reaction Chemotherapy Guideline Nausea Quality of life Vomiting
The authors are grateful to Merve Sarı who assisted in identifying patients.
Conflicts of interest
The authors have no conflicts of interest to declare.
- 3.Lindley CM, Hirsch JD. Nausea and vomiting and cancer patients’ quality of life: a discussion of Professor Selby’s paper. Br J Cancer. 1992;19:S26–9.Google Scholar
- 11.Morrow GR, Roscoe JA, Hickok JT, Stern RM, Pierce HI, King DB, et al. Initial control of chemotherapy-induced nausea and vomiting in patient quality of life. Oncology (Williston Park). 1998;12:32–7.Google Scholar
- 19.Peterson C, Hursti T, Barjeson S, Ãvall-Lundgvist E, Fredrikson M, Farst C, et al. Single high-dose dexamethasone improves the effect of ondansetron on acute chemotherapy-induced nausea and vomiting but impairs the control of delayed symptoms. Support Care Cancer. 1996;4:440–6.CrossRefPubMedGoogle Scholar
- 22.Berger AM, Clark-Snow RA. Nausea and vomiting. In: DeVita Jr VT, Hellman S, Rosenberg SA, editors. Cancer: principles & practice of oncology. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2004.Google Scholar
- 23.Italian Group for Antiemetic Research. Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. J Clin Oncol. 1998;16:2937–42.Google Scholar
- 25.Hesketh P. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the aprepitant protocol 052 study group. J Clin Oncol. 2003;21:4112–9.CrossRefPubMedGoogle Scholar
- 33.Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 2009;10:115–24.CrossRefPubMedGoogle Scholar